Is Coris Bioconcept still active?

Yes, Coris Bioconcept is currently active.

Where is Coris Bioconcept registered?

Coris Bioconcept's registered address is Rue Guillaume Fouquet,Isnes 11, 5032 Gembloux, Belgium.

How many employees does Coris Bioconcept have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2024), Coris Bioconcept reported 31.5 full-time equivalent employees.

What is Coris Bioconcept's annual turnover?

Coris Bioconcept's most recently filed annual turnover (fiscal year ending 31 Dec 2024) was €5,223,181.

Did Coris Bioconcept make a profit or a loss?

Coris Bioconcept's most recently filed annual accounts (fiscal year ending 31 Dec 2024) reported a loss of €471,288.

When did Coris Bioconcept last file annual accounts?

Coris Bioconcept's most recently filed annual accounts cover the fiscal year ending 31 Dec 2024.

Is Coris Bioconcept B Corp certified?

We have no B Corp certification on file for Coris Bioconcept.

Does Coris Bioconcept hold Fairtrade certification?

No, Coris Bioconcept does not currently hold Fairtrade certification.

Coris Bioconcept

Q: What is Coris Bioconcept's legal form?

Besloten Vennootschap (BV) / Société à responsabilité limitée (SRL).

Q: When was Coris Bioconcept founded?

Coris Bioconcept was founded on 16 Oct 1996, making it 29 years old.

Q: What does Coris Bioconcept do?

Coris Bioconcept's registered main activities are Wholesale of pharmaceutical and medical goods, Activities in the field of nutrition, Systematic studies and creative efforts undertaken in various types of math research and development and natural sciences (physics, astronomy, chemistry, medical sciences, biology, etc.), Non-specialised wholesale trade, and Study, development of the production of active ingredients for drug manufacturing. It is also registered for 1 additional activity.

BE 0459.020.430

Copied!

BV/SRL

Status

Active

Founded

16 Oct 1996

Size

Small · 31.5 FTE

Age

29 yrs

Main activity

Wholesale of pharmaceutical and medical goods

Activities

6 activities

Wholesale of pharmaceutical and medical goodsActivities in the field of nutritionSystematic studies and creative efforts undertaken in various types of math research and development and natural sciences (physics, astronomy, chemistry, medical sciences, biology, etc.)Non-specialised wholesale tradeStudy, development of the production of active ingredients for drug manufacturingRetail sale of medical and orthopaedic goods, except corrective glasses, lenses and sunglasses

Financials

Turnover2024

€5.2M-12.6%

Profit / Loss2024

−€471K+44.7%

Equity2024

€5.4M-8.3%

2024	2023	2022	2021
€5,223,181-12.6%	€5,977,824	—	—
-€471,288+44.7%	-€852,803<-1000%	-€27,181+93.1%	-€394,046
€5,427,346-8.3%	€5,916,715-15%	€6,963,027-0.3%	€6,986,285
€1,474,586-13.3%	€1,701,106-1.4%	€1,724,878-23.5%	€2,254,117
€1,614,605-40.9%	€2,733,982-26.3%	€3,711,488-0.7%	€3,737,888
31.5+18.4%	26.6-10.7%	29.8-1.3%	30.2
€165,815-26.2%	€224,730	—	—

Frequently asked questions

01What is Coris Bioconcept's official registered name?

Coris Bioconcept.

02What is Coris Bioconcept's enterprise number (VAT number)?

BE 0459.020.430.

03What is Coris Bioconcept's legal form?

Besloten Vennootschap (BV) / Société à responsabilité limitée (SRL).

04When was Coris Bioconcept founded?

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

	2024	2023	2022	2021
Income statement
	€5,223,181-12.6%	€5,977,824	—	—
	€2,441,626+33.5%	€1,829,671-35.1%	€2,821,606+3.5%	€2,726,326
	€2,112,690+12.2%	€1,883,216-6.7%	€2,017,794+13%	€1,785,579
	€608,117-21.9%	€778,445+532.7%	€123,027-37.1%	€195,650
	-€430,038+50.5%	-€867,918-752%	-€101,864+72.2%	-€366,571
	€321,751+624.3%	-€61,368	—	—
	-€471,288+44.7%	-€852,803<-1000%	-€27,181+93.1%	-€394,046
	€15,147+23.5%	€12,262-42%	€21,159+494.7%	€3,558
Profitability
	46.7%+52.7%	30.6%	—	—
	6.2%+700%	-1.0%	—	—
	-9.0%+36.8%	-14.3%	—	—
	-8.7%+39.8%	-14.4%<-1000%	-0.4%+93.1%	-5.6%
	-6.8%+39%	-11.2%<-1000%	-0.3%+92.7%	-4.3%
Solvency
	€6,901,932-9.4%	€7,617,821-12.3%	€8,687,905-6%	€9,240,401
	€1,343,029+41.1%	€951,789+170.8%	€351,532-12.8%	€403,189
	—	€0-100%	€32,328-1%	€32,657
	€5,427,346-8.3%	€5,916,715-15%	€6,963,027-0.3%	€6,986,285
	78.6%+1.2%	77.7%-3.1%	80.1%+6%	75.6%
	€455,188-28.3%	€634,818+59.8%	€397,204-28.7%	€556,783
	0.08-21.8%	0.11+88.1%	0.06-28.4%	0.08
	€1,474,586-13.3%	€1,701,106-1.4%	€1,724,878-23.5%	€2,254,117
	0.27-5.5%	0.29+16.1%	0.25-23.2%	0.32
Liquidity
	€1,614,605-40.9%	€2,733,982-26.3%	€3,711,488-0.7%	€3,737,888
	€1,073,608-15.4%	€1,269,075-7.5%	€1,372,373-5%	€1,444,531
	€1,485,798+52.5%	€974,529-25.7%	€1,312,414+99.8%	€656,793
	€544,027+19.1%	€456,632-10.1%	€507,831-56.8%	€1,176,622
	€1,017,239+10.8%	€918,435-19.9%	€1,146,157-32.2%	€1,691,741
	2.63+6.4%	2.48+0.7%	2.46-12.8%	2.82
	€3,280,946-23.8%	€4,308,256-23.7%	€5,648,652-17.2%	€6,824,626
Efficiency
	104 days+74.5%	60 days	—	—
Profit appropriation
	€4,737,5880%	€4,737,5880%	€4,737,5880%	€4,737,588
	€414,136-53.2%	€885,424-49.1%	€1,738,227-1.5%	€1,765,408

Sources

NBB — Nationale Bank van België

	2024	2023	2022	2021
Income statement
	€5,223,181-12.6%	€5,977,824	—	—
	€2,441,626+33.5%	€1,829,671-35.1%	€2,821,606+3.5%	€2,726,326
	€2,112,690+12.2%	€1,883,216-6.7%	€2,017,794+13%	€1,785,579
	€608,117-21.9%	€778,445+532.7%	€123,027-37.1%	€195,650
	-€430,038+50.5%	-€867,918-752%	-€101,864+72.2%	-€366,571
	€321,751+624.3%	-€61,368	—	—
	-€471,288+44.7%	-€852,803<-1000%	-€27,181+93.1%	-€394,046
	€15,147+23.5%	€12,262-42%	€21,159+494.7%	€3,558
Profitability
	46.7%+52.7%	30.6%	—	—
	6.2%+700%	-1.0%	—	—
	-9.0%+36.8%	-14.3%	—	—
	-8.7%+39.8%	-14.4%<-1000%	-0.4%+93.1%	-5.6%
	-6.8%+39%	-11.2%<-1000%	-0.3%+92.7%	-4.3%
Solvency
	€6,901,932-9.4%	€7,617,821-12.3%	€8,687,905-6%	€9,240,401
	€1,343,029+41.1%	€951,789+170.8%	€351,532-12.8%	€403,189
	—	€0-100%	€32,328-1%	€32,657
	€5,427,346-8.3%	€5,916,715-15%	€6,963,027-0.3%	€6,986,285
	78.6%+1.2%	77.7%-3.1%	80.1%+6%	75.6%
	€455,188-28.3%	€634,818+59.8%	€397,204-28.7%	€556,783
	0.08-21.8%	0.11+88.1%	0.06-28.4%	0.08
	€1,474,586-13.3%	€1,701,106-1.4%	€1,724,878-23.5%	€2,254,117
	0.27-5.5%	0.29+16.1%	0.25-23.2%	0.32
Liquidity
	€1,614,605-40.9%	€2,733,982-26.3%	€3,711,488-0.7%	€3,737,888
	€1,073,608-15.4%	€1,269,075-7.5%	€1,372,373-5%	€1,444,531
	€1,485,798+52.5%	€974,529-25.7%	€1,312,414+99.8%	€656,793
	€544,027+19.1%	€456,632-10.1%	€507,831-56.8%	€1,176,622
	€1,017,239+10.8%	€918,435-19.9%	€1,146,157-32.2%	€1,691,741
	2.63+6.4%	2.48+0.7%	2.46-12.8%	2.82
	€3,280,946-23.8%	€4,308,256-23.7%	€5,648,652-17.2%	€6,824,626
Efficiency
	104 days+74.5%	60 days	—	—
Profit appropriation
	€4,737,5880%	€4,737,5880%	€4,737,5880%	€4,737,588
	€414,136-53.2%	€885,424-49.1%	€1,738,227-1.5%	€1,765,408

2024

2023

2022

2021

Income statement

€5,223,181-12.6%

€5,977,824

—

€2,441,626+33.5%

€1,829,671-35.1%

€2,821,606+3.5%

€2,726,326

€2,112,690+12.2%

€1,883,216-6.7%

€2,017,794+13%

€1,785,579

€608,117-21.9%

€778,445+532.7%

€123,027-37.1%

€195,650

-€430,038+50.5%

-€867,918-752%

-€101,864+72.2%

-€366,571

€321,751+624.3%

-€61,368

—

-€471,288+44.7%

-€852,803<-1000%

-€27,181+93.1%

-€394,046

€15,147+23.5%

€12,262-42%

€21,159+494.7%

€3,558

Profitability

46.7%+52.7%

30.6%

—

6.2%+700%

-1.0%

—

-9.0%+36.8%

-14.3%

—

-8.7%+39.8%

-14.4%<-1000%

-0.4%+93.1%

-5.6%

-6.8%+39%

-11.2%<-1000%

-0.3%+92.7%

-4.3%

Solvency

€6,901,932-9.4%

€7,617,821-12.3%

€8,687,905-6%

€9,240,401

€1,343,029+41.1%

€951,789+170.8%

€351,532-12.8%

€403,189

—

€0-100%

€32,328-1%

€32,657

€5,427,346-8.3%

€5,916,715-15%

€6,963,027-0.3%

€6,986,285

78.6%+1.2%

77.7%-3.1%

80.1%+6%

75.6%

€455,188-28.3%

€634,818+59.8%

€397,204-28.7%

€556,783

0.08-21.8%

0.11+88.1%

0.06-28.4%

0.08

€1,474,586-13.3%

€1,701,106-1.4%

€1,724,878-23.5%

€2,254,117

0.27-5.5%

0.29+16.1%

0.25-23.2%

0.32

Liquidity

€1,614,605-40.9%

€2,733,982-26.3%

€3,711,488-0.7%

€3,737,888

€1,073,608-15.4%

€1,269,075-7.5%

€1,372,373-5%

€1,444,531

€1,485,798+52.5%

€974,529-25.7%

€1,312,414+99.8%

€656,793

€544,027+19.1%

€456,632-10.1%

€507,831-56.8%

€1,176,622

€1,017,239+10.8%

€918,435-19.9%

€1,146,157-32.2%

€1,691,741

2.63+6.4%

2.48+0.7%

2.46-12.8%

2.82

€3,280,946-23.8%

€4,308,256-23.7%

€5,648,652-17.2%

€6,824,626

Efficiency

104 days+74.5%

60 days

—

Profit appropriation

€4,737,5880%

€4,737,588

€414,136-53.2%

€885,424-49.1%

€1,738,227-1.5%

€1,765,408

Coris Bioconcept

Activities

Financials

Frequently asked questions

All locations

All locations